Martin Lord
Forskare vid Institutionen för farmaci; Biologiska läkemedel; Immunonkologi
- E-post:
- martin.lord@uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 580
751 23 UPPSALA
Publikationer
Senaste publikationer
Ingår i Molecular Therapy: Oncology, 2025
- DOI för Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
- Ladda ner fulltext (pdf) av Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
Ingår i Nature Communications, 2024
- DOI för A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice
- Ladda ner fulltext (pdf) av A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice
Ingår i Blood, s. 1953-1964, 2024
Ingår i BMC Cancer, 2023
- DOI för Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
- Ladda ner fulltext (pdf) av Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
Ingår i ChemBioChem, 2023
- DOI för Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
- Ladda ner fulltext (pdf) av Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
Alla publikationer
Artiklar i tidskrift
Ingår i Molecular Therapy: Oncology, 2025
- DOI för Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
- Ladda ner fulltext (pdf) av Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
Ingår i Nature Communications, 2024
- DOI för A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice
- Ladda ner fulltext (pdf) av A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice
Ingår i Blood, s. 1953-1964, 2024
Ingår i BMC Cancer, 2023
- DOI för Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
- Ladda ner fulltext (pdf) av Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
Ingår i ChemBioChem, 2023
- DOI för Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
- Ladda ner fulltext (pdf) av Epitopes displayed in a cyclic peptide scaffold bind SARS-CoV-2 antibodies
Ingår i Advanced Therapeutics, 2022
- DOI för An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
- Ladda ner fulltext (pdf) av An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Ingår i Immunity, Inflammation and Disease, 2022
- DOI för Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
- Ladda ner fulltext (pdf) av Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
Ingår i Journal of Internal Medicine, s. 72-80, 2022
- DOI för Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
- Ladda ner fulltext (pdf) av Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
Ingår i New Biotechnology, s. 9-19, 2021
- DOI för Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
- Ladda ner fulltext (pdf) av Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
Ingår i PLOS ONE, 2021
- DOI för Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
- Ladda ner fulltext (pdf) av Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
Ingår i PLOS ONE, 2021
- DOI för An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
- Ladda ner fulltext (pdf) av An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Ingår i Cancers, 2021
- DOI för Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
- Ladda ner fulltext (pdf) av Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Ingår i International Immunopharmacology, 2021
- DOI för Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
- Ladda ner fulltext (pdf) av Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients